1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 May 2024
Admin
News Article

Oxford Nanopore & Twist Bioscience Partners to Launch PGx Beta Programme

Oxford Nanopore collaborates with Twist Bioscience to launch PGx Beta Programme and advance personalised medicine

Overview

Oxford Nanopore Technologies (Oxford Nanopore) announced the launch of a new Pharmacogenomics (PGx) Beta Programme to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.

PGx Solution

The newly unveiled Twist-Oxford Nanopore long-read PGx solution, which is now available for research use, is designed to provide unambiguous genetic results in a single end-to-end workflow from sample to PGx star allele call, alleviating the need for time-consuming and costly follow-up tests in contrast to conventional methods. The beta programme aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform.

Words from Oxford Nanopore

“Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore.
“Combined with Twist’s technology, Oxford Nanopore’s value proposition for PGx lies in the ability to deliver richer data through long reads, ultra-fast sequencing speed, accessible form factor and flexibility in terms of throughput, making it an ideal choice for comprehensive and efficient genetic analysis in clinical settings.""

The CYP2D6 Gene & PGx Beta Programme

The PGx beta programme has successfully achieved full resolution of the CYP2D6 gene in a single assay.
CYP2D6 is responsible for metabolizing 20% of drugs on the market and is one of the most challenging genes to sequence due to its complex structure.
The Twist Alliance Long-Read PGx Panel coupled with Chinook, Oxford Nanopore’s CYP2D6 -specific allele caller, demonstrated 100% CYP2D6 reference concordance, overcoming the limitations of conventional sequencing technologies.

Key features of the PGx Beta Programme include:

Comprehensive CYP2D6 assay: Achieving full gene resolution in a single test.
Integration with Oxford Nanopore devices: Twist’s Library Preparation Reagents and Target Enrichment Panels will be integrated with Oxford Nanopores’ MinION and PromethION flow cells, enabling flexibility in throughput and offering customers a seamless and powerful toolset for Oxford Nanopore sequencing.
Continuous innovation and compatibility testing: Ongoing evaluations to ensure combability with Twist’s hybrid capture panels, including exploration of the Twist Alliance Dark Genes Panel and the Twist Exome 2.0, potentially broadening the scope of genetic research and clinical applications.

Words from CEO: Twist Bioscience

“Oxford Nanopore’s technology provides genetic analysis and through our collaboration and the Pharmacogenomics Beta Programme, we’re able to expand the reach of our NGS products and provide researchers with a tool to develop personalised therapies. We’re looking forward to progressing through the Beta Program and exploring additions to our collaboration,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
“The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!